TERNS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.56 USD | -0.65% |
|
-11.28% | -29.74% |
| Apr. 10 | Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer | CI |
| Mar. 27 | UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating | MT |
Financials (USD)
| Sales 2024 * | 1.67M | Sales 2025 * | 2.17M | Capitalization | 297M |
|---|---|---|---|---|---|
| Net income 2024 * | -108M | Net income 2025 * | -127M | EV / Sales 2024 * | 55.1 x |
| Net cash position 2024 * | 205M | Net cash position 2025 * | 186M | EV / Sales 2025 * | 50.8 x |
| P/E ratio 2024 * |
-3.29
x | P/E ratio 2025 * |
-3.25
x | Employees | 66 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.48% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.32% | ||
| 1 week | -11.88% | ||
| Current month | -29.88% | ||
| 1 month | -24.40% | ||
| 3 months | -11.71% | ||
| 6 months | -20.00% | ||
| Current year | -29.12% |
1 week
4.37
5.16
1 month
4.377.35
Current year
4.378.68
1 year
3.2614.04
3 years
1.4522.24
5 years
1.4528.36
10 years
1.4528.36
| Managers | Title | Age | Since |
|---|---|---|---|
Amy Burroughs
CEO | Chief Executive Officer | 53 | Feb. 06 |
Erin Quirk
PSD | President | 53 | 18-12-31 |
Mark Vignola
DFI | Director of Finance/CFO | 46 | 20-08-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Fellows
CHM | Chairman | 67 | 20-11-30 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 20-11-30 |
Carl Gordon
BRD | Director/Board Member | 59 | 18-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 4.56 | -0.65% | 866 472 |
| 24-04-18 | 4.59 | +1.10% | 694,069 |
| 24-04-17 | 4.54 | -2.78% | 762,894 |
| 24-04-16 | 4.67 | -7.71% | 656,228 |
| 24-04-15 | 5.06 | -1.56% | 695,703 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.59
USD
Average target price
14.21
USD
Spread / Average Target
+209.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.12% | 297M | |
| -1.82% | 41.35B | |
| +41.93% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- TERN Stock
